ACRX Stock Forecast 2025-2026
Distance to ACRX Price Targets
ACRX Price Momentum
10 Quality Stocks Worth Considering Now
Researching AcelRx (ACRX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ACRX and similar high-potential opportunities.
Latest ACRX Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, ACRX has a bullish consensus with a median price target of $4.63 (ranging from $4.25 to $5.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $0.64, the median forecast implies a 624.5% upside. This outlook is supported by 3 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ed Arce at HC Wainwright & Co., projecting a 682.4% upside. Conversely, the most conservative target is provided by James Molloy at Alliance Global Partners, suggesting a 565.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACRX Analyst Ratings
ACRX Price Target Range
Latest ACRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 22, 2024 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Dec 7, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Oct 2, 2023 | Alliance Global Partners | James Molloy | Buy | Initiates | $4.25 |
| Sep 25, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $5.00 |
| Aug 18, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Upgrade | $8.00 |
| Mar 14, 2022 | HC Wainwright & Co. | Ed Arce | Neutral | Downgrade | $0.00 |
| Aug 17, 2021 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $5.00 |
| Aug 13, 2020 | Credit Suisse | Underperform | Maintains | $0.84 | |
| Jul 20, 2020 | Credit Suisse | Evan Seigerman | Underperform | Downgrade | $0.69 |
| Mar 17, 2020 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $7.00 |
| Mar 17, 2020 | H.C. Wainwright | Buy | Maintains | $0.00 | |
| Nov 11, 2019 | Credit Suisse | Neutral | Downgrade | $2.00 | |
| Apr 24, 2019 | B. Riley FBR | Buy | Initiates | $0.00 | |
| Feb 15, 2019 | Credit Suisse | Outperform | Initiates | $0.00 | |
| Oct 23, 2018 | B. Riley FBR | Buy | Initiates | $0.00 | |
| Oct 15, 2018 | Jefferies | Buy | Upgrade | $0.00 | |
| Oct 10, 2018 | Ladenburg Thalmann | Buy | Reiterates | $10.00 | |
| Aug 16, 2018 | Ladenburg Thalmann | Buy | Initiates | $0.00 | |
| Jul 13, 2018 | Oppenheimer | Perform | Initiates | $0.00 | |
| Jun 12, 2018 | Cantor Fitzgerald | Overweight | Initiates | $0.00 |
AcelRx Pharmaceuticals Inc (ACRX) Competitors
The following stocks are similar to AcelRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AcelRx Pharmaceuticals Inc (ACRX) Financial Data
AcelRx Pharmaceuticals Inc has a market capitalization of $14.58M with a P/E ratio of 0.1x. The company generates $370,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -76.9% quarter-over-quarter, while maintaining an operating margin of -2,828.2% and return on equity of -51.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
AcelRx Pharmaceuticals Inc (ACRX) Business Model
About AcelRx Pharmaceuticals Inc
Develops therapies for acute pain management.
The company focuses on developing and commercializing innovative therapies for moderate-to-severe acute pain, primarily through its lead product candidates, DSUVIA and DZUVEO. AcelRx generates revenue by marketing these products and leveraging its pipeline of other pain management solutions, including patient-controlled analgesia systems and various injectable formulations.
AcelRx is involved in ongoing clinical trials for several of its product candidates, targeting conditions such as cancer breakthrough pain and procedural anxiety. The company has a history of name changes and was founded in 2005, with its headquarters located in Hayward, California.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Employees
19
CEO
Mr. Vincent J. Angotti
Country
United States
IPO Year
2011
Website
www.acelrx.comAcelRx Pharmaceuticals Inc (ACRX) Latest News & Analysis
AcelRx Pharmaceuticals has rebranded as Talphera, Inc. and will begin trading on Nasdaq under the symbol "TLPH" starting January 10, 2024.
The name change to Talphera and its Nasdaq debut under "TLPH" signals a strategic shift, potentially enhancing market perception and opening new investment opportunities in specialty pharmaceuticals.
AcelRx Pharmaceuticals published a study on U.S. physician anticoagulation practices during CRRT for acute kidney injury, noting increased CRRT use and challenges with existing anticoagulants.
Increased CRRT usage and challenges with current anticoagulants highlight potential demand for innovative therapies, influencing AcelRx's market positioning and growth prospects.
AcelRx Pharmaceuticals will hold its Q3 2023 earnings conference call on November 8, 2023, at 4:30 PM ET, featuring key executives and analysts.
AcelRx's Q3 earnings call may reveal financial performance and strategic direction, impacting stock valuation and investor sentiment in the biotech sector.
Niyad™ received FDA IDE approval in Q3 and will start its registrational study this quarter, with topline data expected mid-2024. The company has $13.4M in cash and closed a $26.3M financing deal.
FDA approval of the Niyad IDE and upcoming registrational study signals potential for product launch, enhancing growth prospects. Strong financing ensures operational stability and development funding.
Two KOLs will discuss anticoagulants in dialysis and the Niyad study protocol during a webcast on December 6, 2023, at 11:00 a.m. ET. Registration is required to attend.
The discussion on anticoagulants in dialysis and the Niyad study could impact healthcare stocks, influencing investment strategies in the biotech sector.
AcelRx Pharmaceuticals (Nasdaq: ACRX) will release its Q3 2023 financial results on November 8, 2023, after market close, followed by a webcast and conference call at 4:30 p.m.
AcelRx's upcoming financial results and conference call could impact stock performance and investor sentiment, providing insights into its financial health and future prospects.
Frequently Asked Questions About ACRX Stock
What is AcelRx Pharmaceuticals Inc's (ACRX) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, AcelRx Pharmaceuticals Inc (ACRX) has a median price target of $4.63. The highest price target is $5.00 and the lowest is $4.25.
Is ACRX stock a good investment in 2025?
According to current analyst ratings, ACRX has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.64. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACRX stock?
Wall Street analysts predict ACRX stock could reach $4.63 in the next 12 months. This represents a 624.5% increase from the current price of $0.64. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AcelRx Pharmaceuticals Inc's business model?
The company focuses on developing and commercializing innovative therapies for moderate-to-severe acute pain, primarily through its lead product candidates, DSUVIA and DZUVEO. AcelRx generates revenue by marketing these products and leveraging its pipeline of other pain management solutions, including patient-controlled analgesia systems and various injectable formulations.
What is the highest forecasted price for ACRX AcelRx Pharmaceuticals Inc?
The highest price target for ACRX is $5.00 from Ed Arce at HC Wainwright & Co., which represents a 682.4% increase from the current price of $0.64.
What is the lowest forecasted price for ACRX AcelRx Pharmaceuticals Inc?
The lowest price target for ACRX is $4.25 from James Molloy at Alliance Global Partners, which represents a 565.0% increase from the current price of $0.64.
What is the overall ACRX consensus from analysts for AcelRx Pharmaceuticals Inc?
The overall analyst consensus for ACRX is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $4.63.
How accurate are ACRX stock price projections?
Stock price projections, including those for AcelRx Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
